By vgreene, 21 December, 2020 Study considerations other COVID 19 tx allowed per hospital protocols 12 pts received corticosteroid tx 6 6 DEX median sx onset 8 days before enrollment
By vgreene, 21 December, 2020 KEY FINDINGS baricitinib RDV superior to RDV alone in reducing recovery time and accelerating clinical status improvement particularly in pts w high flow O2 or noninvasive vent
By vgreene, 21 December, 2020 Primary outcome of time to recovery baricitinib 7 days vs placebo 8 days RR 1 16 95 CI 1 01 1 32 in pts w high flow O2 or noninvasive vent baricitinib 10 days vs placebo 18 days RR 1 51 95 CI 1 1 2 08 no difference in 28 day mortality fewer serious ADRs a
By vgreene, 21 December, 2020 Multicenter randomized double blind study 1 033 hospitalized pts mean age 55 4y w COVID 19 68 mod dz 32 severe dz received baricitinib 4 md PO qd x14 days n 515 or placebo n 518 both groups received RDV 200 mg IV x1 then 100 mg IV qd x9 days other experim
By vgreene, 21 December, 2020 Study considerations other COVID 19 tx allowed per hospital protocols 12 pts received corticosteroid tx 6 6 DEX median sx onset 8 days before enrollment
By vgreene, 21 December, 2020 KEY FINDINGS baricitinib RDV superior to RDV alone in reducing recovery time and accelerating clinical status improvement particularly in pts w high flow O2 or noninvasive vent
By vgreene, 21 December, 2020 Note For published studies on combo tx w baricitinib refer to JAK inhibitors
By vgreene, 21 December, 2020 Consider consult referral to Allergy Immunology specialist and or ID specialist for additional w u recs
